Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Suspected Cancer: recognition and referralStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 March 2026
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [TSID12177]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC